Preemptive Antiviral Therapy Prevents Chronic Hepatitis C Infection in Heart Transplant Patients Who Receive Infected Donor Organs
American Association for the Study of Liver Diseases (AASLD)SAN FRANCISCO – Preliminary data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver Diseases – found that pre-emptive administration of pan-genotypic, direct-acting antiviral therapy prevents chronic hepatitis C virus infection in hepatitis C-negative cardiac transplant patients who receive donor hearts infected with the virus.